BaseLaunch announces a new partnership with AbbVie
Further strengthens BaseLaunch's global pharma industry partnerships
Further strengthens BaseLaunch's global pharma industry partnerships
Phase I data for tuvusertib, lead asset from the company’s unique portfolio of DDR inhibitors
Acquisition will advance Merck’s integrated offering for viral vector manufacturing
The funds raised from the Whitathon run are utilized to treat underprivileged children suffering from Retinoblastoma
95.7% of patients responded to Breyanzi in the TRANSCEND FL trial
35,000 doctors from across India pledged their support for the initiative to raise awareness about cardiovascular diseases
Annapurna will lead the company in India ensuring patient access to its highly innovative medicines and vaccines
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
Subscribe To Our Newsletter & Stay Updated